A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants
Latest Information Update: 15 Mar 2023
At a glance
- Drugs SRK-001 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Sarkana Pharma
- 09 Mar 2023 Status changed from recruiting to discontinued.
- 03 Jan 2022 Status changed from not yet recruiting to recruiting.
- 21 Dec 2021 New trial record